☆ 4.8 Review

The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy

Ahmad Y. Abuhelwa et al.

Summary: This study validated and enhanced the discrimination ability of the Bellmunt risk score for immune checkpoint inhibitor therapy in patients with urothelial carcinoma. The inclusion of C-reactive protein in the Bellmunt score improved its performance and allowed for better patient stratification in clinical trials.

CLINICAL GENITOURINARY CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score

Bernhard Scheiner et al.

Summary: The CRAFITY score is associated with survival and radiological response in patients receiving PD-(L)1 immunotherapy for hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up

Elin Aamdal et al.

Summary: Ipilimumab has shown safety and efficacy in a real-world setting for patients with advanced melanoma, with a treatment interruption rate of 38%. Biomarkers such as poor performance status, elevated lactate dehydrogenase, and C-reactive protein were identified for predicting treatment outcomes.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC

Yuki Takeyasu et al.

Summary: PD-L1 expression and absence of liver metastasis are significant predictors for a better response to pembrolizumab in patients with strongly positive PD-L1 NSCLC. Higher PD-L1 expression and lack of liver metastasis were associated with higher objective response rate and longer progression-free survival in these patients.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Gastroenterology & Hepatology

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study

Sho Sato et al.

Summary: The study found that nivolumab showed safety and survival benefits in patients with previously treated unresectable or recurrent gastric cancer. Patients with low C-reactive protein level, occurrence of irAEs, high albumin level, high lymphocyte count, and differentiated histological type may have better treatment outcomes. Having four or more good prognostic factors can help identify likely long-term survivors.

ANNALS OF GASTROENTEROLOGICAL SURGERY (2021)

Add to Collection

Article Oncology

C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab

Eduard Roussel et al.

Summary: This study assessed the impact of systemic inflammation markers such as CRP and NLR on outcomes of m-ccRCC patients receiving nivolumab. Elevated baseline CRP and NLR levels were associated with worse OS and PFS. Including CRP in the IMDC prognostic model improved its predictive ability.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection

Article Engineering, Biomedical

Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer

Zachary R. Stephen et al.

Summary: Immunotherapy has shown success in certain cancers, and combinational approaches with hyperthermia therapy are being explored to enhance its effectiveness. Nanoparticle-based hyperthermia increases tumor immunogenicity and permeability, particularly effective in solid tumors.

ADVANCED HEALTHCARE MATERIALS (2021)

Add to Collection

Article Oncology

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Gil Awada et al.

Summary: Pembrolizumab improves survival in advanced melanoma patients by targeting programmed cell death 1. This study analyzed baseline clinical characteristics and gene expression profiling in relation to survival in patients treated with pembrolizumab, finding organ function and systemic inflammatory/immunologic status to be key predictors of survival. Novel biomarkers such as baseline DNA mutations and total metabolic tumor volume were also identified as predictive factors.

CANCERS (2021)

Add to Collection

Article Oncology

Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors

Shinkichi Takamori et al.

Summary: The study analyzed 304 advanced or recurrent NSCLC patients treated with ICI monotherapy to evaluate the clinical utility of inflammatory indices like GPS, mGPS, and CAR in predicting survival outcomes. Results showed that GPS was significantly correlated with disease control rate and was superior to mGPS and CAR in predicting overall survival. GPS in combination with performance status effectively predicted survival at 1 year and was identified as an independent predictor of progression-free survival and overall survival in multivariable analysis.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors

Jacqueline T. Brown et al.

Summary: The study investigated the impact of modified Glasgow prognostic score (mGPS) on survival outcomes in patients with metastatic urothelial cell carcinoma (mUC) receiving immune checkpoint inhibitors (ICI). The results showed that mGPS was associated with survival outcomes in patients with mUC treated with ICIs and could help clinicians prognosticate for patients beginning immunotherapy.

ONCOLOGIST (2021)

Add to Collection

Review Immunology

Therapeutic Lowering of C-Reactive Protein

Rachel V. Jimenez et al.

Summary: CRP levels are typically low in healthy individuals, but can rise rapidly in response to tissue damage and inflammation. It is commonly believed that CRP's biological actions are only evident when blood levels are elevated, however studies have shown that even at baseline levels CRP exerts important biological effects.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms

Lawrence A. Potempa et al.

Summary: C-reactive protein (CRP) is a protein that appears in blood during acute episodes of infectious diseases and can be used as a diagnostic marker for inflammation in various diseases. By dissociating into monomeric form, CRP can provide both pro-inflammatory and anti-inflammatory activities. Understanding the factors that influence the dissociation of CRP into different isoforms allows for a reevaluation of previous studies on its role as a biological response modifier.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan

Motohiro Fujiwara et al.

Summary: This study investigated the efficacy and safety profile of pembrolizumab therapy in Japanese patients with metastatic urothelial carcinoma. The presence of liver metastasis, worse performance status, elevated serum lactate dehydrogenase, and increased C-reactive protein were identified as predictors of shorter overall survival. The findings from this study may be valuable for clinical physicians.

CANCER REPORTS (2021)

Add to Collection

Article Oncology

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

Rosalinda Arends et al.

Summary: Durvalumab treatment for HNSCC patients was associated with different circulating protein levels, with IL-6, C-reactive protein, and osteocalcin showing significant correlations with overall survival. Validation datasets confirmed the independent associations of IL-6 and osteocalcin with survival, indicating their potential as biomarkers for clinical outcomes.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Oncology

Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma

Hiroki Ishihara et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)

Add to Collection

Article Oncology

Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status

Yuichi Adachi et al.

CANCER MEDICINE (2020)

Add to Collection

Article Oncology

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study

Jakob M. Riedl et al.

CANCERS (2020)

Add to Collection

Article Oncology

The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis

Yanglan Chen et al.

CANCER MEDICINE (2020)

Add to Collection

Review Immunology

C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights

Peter C. Hart et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma

Suguru Shirotake et al.

ANTICANCER RESEARCH (2019)

Add to Collection

Article Oncology

Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer

Shotaro Yasuoka et al.

ANTICANCER RESEARCH (2019)

Add to Collection

Review Immunology

Inflammation and Cancer: Triggers, Mechanisms, and Consequences

Florian R. Greten et al.

IMMUNITY (2019)

Add to Collection

Article Multidisciplinary Sciences

The value of C-reactive protein as an independent prognostic indicator for disease specific survival in patients with soft tissue sarcoma: A meta-analysis

Xiaolin Wang et al.

PLOS ONE (2019)

Add to Collection

Review Immunology

The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review

Barbara Seliger

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Oncology

Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Fumihiro Shoji et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy

Mehmet A. Bilen et al.

CANCER (2019)

Add to Collection

Article Oncology

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Immunology

Role of C-Reactive Protein at Sites of Inflammation and Infection

Nicola R. Sproston et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Review Oncology

Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers A Systematic Review and Meta-analysis

Georgia Ritchie et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Psychology, Multidisciplinary

Changes in physical activity behavior and C-reactive protein in breast cancer patients

Catherine M. Sabiston et al.

ANNALS OF BEHAVIORAL MEDICINE (2018)

Add to Collection

Article Oncology

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Markus V. Heppt et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

Yuko Oya et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

Yoshio Nakamura et al.

ONCOTARGET (2016)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Oncology

Cancer prevention and therapy through the modulation of the tumor microenvironment

Stephanie C. Casey et al.

SEMINARS IN CANCER BIOLOGY (2015)

Add to Collection

Review Gastroenterology & Hepatology

Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review

Lewis Stevens et al.

HPB (2015)

Add to Collection

Article Multidisciplinary Sciences

Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis

Liang Zhou et al.

SCIENTIFIC REPORTS (2015)

Add to Collection

Article Oncology

Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma

Sofie Wilgenhof et al.

JOURNAL OF IMMUNOTHERAPY (2013)

Add to Collection

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

Add to Collection

Review Biochemistry & Molecular Biology

The tumor microenvironment and its role in promoting tumor growth

T. L. Whiteside

ONCOGENE (2008)

Add to Collection

Article Medicine, General & Internal

Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study

MA Albert et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.